Robert Hubbard, Ph.D. Email & Phone Number

Sevenoaks, GB

Developing strategy for a novel platform approach for oncologyManaging all aspects of drug discovery - chemistry, pharmacology and DMPKParticipating in fundraising to support platform expansion

Cambridge, MA, US

Execution of medicinal chemistry on a novel target for neurodegenerationDiligence novel targets from the RABID-seqManaging external CROs across medicinal chemistry and ADME/DMPK

Cambridge, MA, US

Operator in Residence for Amplify, which is a pre-commercial translation program at MGB Innovation. Identification of technologies (diagnostics, therapeutics, devices) with high commercial potential within the MGB system. Interaction with KOLs and VCs both internal and external to MGBSeed-level company creation

Communicate objectives and timing of research deliverables to Board and FoundersMeet with VCs to discuss the science of our novel approach to protein degradationResponsible for cross-discipline CRO management

San Diego, CA, US

Project Team Leader focused on harnessing targeted protein degradation towards novel biological target classes.Optimized covalent ligand hits to potent targeted protein degraders.Managed a team of both internal and external chemists. Performed in silico assessment of physical properties of complex synthetic targets

San Diego, California, US

• Expand client base and define new opportunities for Crown Bioscience along the West Coast, focusing in Southern California
• Present Crown Bioscience’s vast capabilities (in vitro/ in vivo) in the Oncology and Immuno-Oncology space

Summit, New Jersey, US

• Orchestrated delivery of a “First-In-Class” kinase inhibitor from the initial synthesis to candidate nomination. Unified project team to streamline timeline requiring key assays be performed in parallel to accommodate.
• Parlayed chemical matter from a novel cell-based screen through H2L, LI, LO
• Communicated the team goals and project team progress to senior management on a quarterly basis.
• Worked with various disciplines (in vitro/ in vivo pharmacology, DMPK, toxicology, biochemistry) to address critical project issues.
• Managed collaborations between Celgene and various external Contract Research Organizations (US, China, Europe), teams ranging from 2-10 FTE.
• Capitalized on recent interest on immune checkpoint biologics by advocating exploring small-molecule therapeutics for Immuno-oncology. Collaborated with scientists across three sites to craft a cohesive small-molecule.

Abbott Park, Illinois, US

• Analyzed patent literature to define optimal conjugation procedures and payloads for internal antibody drug conjugate testing.
• Augmented Abbott’s computational team and performed in silico docking and scoring simulations to find novel chemical matter for Epigenetic targets. Cheminformatic tools used: Maestro, Pipeline Pilot, Seurat, Spotfire.

Abbott Park, Illinois, US

• Recruited/managed Biochemist, Medicinal Chemist, Pharmaceutical Development Scientist and Nucleic Acid Chemist to generate novel platform for in vivo delivery of siRNA.
• Directed the synthesis of innovative lipids for formulation into siRNA-based nanoparticles.
• Successfully synthesized the complex natural product, Pladienolide, an instrumental material for validating a novel oncology target.
• Launched a Fragment-Based Drug Design effort utilizing a Nuclear Magnetic Resonance screen. Elaboration of resulting identified matter led to nomination of a Preclinical Candidate.

Abbott Park, Illinois, US

• Proposed literature inspired kinase program. Examined screening hits from a previous HTS screen and determined a different construct of the protein was needed.
• Developed chemical matter from the subsequent screen using SBDD. Prepared mg to kg quantities of intermediates and/ or final compounds for the project team.
• Initiated a cell-based screen to identify novel Oncology targets. Triaged hits from High-Throughput Screening (HTS) campaign to identify tractable chemical matter.

Brentford, Middlesex, GB

• Optimized a series of kinase inhibitors for an oncology indication.
• Structure Activity Relationship (SAR) evaluation of the scaffold revealed a novel mechanism of irreversibility inhibiting the target kinase.
• Generated a class of potent, stable and selective irreversible inhibitors of the ErbB-family of receptor tyrosine kinases.

Stanford, CA, US

Completed the total synthesis of (-)-Laulimalide and developed two novel Rh-catalyzed reactions.

Chemistry

Ph.D., Chemistry

M.S., Chemistry

B.S., Chemistry